Dexcom welcomed the advocates to a photoshoot in Los Angeles that included Grammy-nominated artist, actor, producer and ...

Dexcom’s World Diabetes Day campaign provides a platform for the selected individuals to advocate for diabetes awareness ...

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

In a report released today, Suraj Kalia from Oppenheimer maintained a Hold rating on Dexcom. The company’s shares closed yesterday at $68.20. Take advantage of TipRanks Premium at 50% off! Unlock ...

DexCom has remained profitable over the last twelve months with $571.5 million in net income and maintains a "GREAT" overall financial health score according to InvestingPro. Investors seeking deeper ...

DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...

DexCom Inc. (DXCM) reported its third-quarter earnings for 2025, surpassing analysts’ expectations with an EPS of $0.61 compared to a forecasted $0.57, marking a 7.02% earnings surprise. Revenue also ...

As of October 30, 2025, the average one-year price target for DexCom is $102.13/share. The forecasts range from a low of $85.07 to a high of $126.00. The average price target represents an increase of ...

SAN DIEGO - Dexcom, Inc. (NASDAQ:DXCM), a glucose biosensing technology company with a market capitalization of $27.69 billion and an "GREAT" financial health rating according to InvestingPro, ...